Andrew W Hutcheon
Overview
Explore the profile of Andrew W Hutcheon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
875
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eremin O, Walker M, Simpson E, Heys S, Ah-See A, Hutcheon A, et al.
Breast
. 2008 Nov;
18(1):17-25.
PMID: 19008099
Eighty women undergoing multimodality treatment for large (>4cm) or locally advanced (T3, T4, Tx, N2), breast cancers participated in a randomised controlled trial (RCT) to evaluate the immuno-modulatory effects of...
2.
Fite A, Goua M, Wahle K, Schofield A, Hutcheon A, Heys S
Prostaglandins Leukot Essent Fatty Acids
. 2007 Sep;
77(2):87-96.
PMID: 17900885
Response rates of tumours to docetaxel (DOCT) are 45-60% in advanced breast cancer but problems associated with side effects, drug resistance and high costs occur. Conjugated linoleic acids (CLAs) also...
3.
McDermott G, Welch A, Staff R, Gilbert F, Schweiger L, Semple S, et al.
Breast Cancer Res Treat
. 2006 Aug;
102(1):75-84.
PMID: 16897427
Unlabelled: We have compared 2-deoxy-2-[(18)F]-fluoro-D-glucose positron emission tomography (FDG-PET) images of large or locally advanced breast cancers (LABC) acquired during Anthracycline-based chemotherapy. The purpose was to determine whether there is...
4.
Chaturvedi S, McLaren C, Schofield A, Ogston K, Sarkar T, Hutcheon A, et al.
Breast Cancer Res Treat
. 2005 Sep;
93(2):151-8.
PMID: 16187235
This study aimed to evaluate patterns of local and distant disease recurrence in patients having primary chemotherapy and compared patterns of relapse in patients with a complete pathological response with...
5.
Heys S, Chaturvedi S, Hutcheon A, Sarkar T
World J Surg Oncol
. 2005 Aug;
3:54.
PMID: 16117834
Background: A major challenge facing us is the provision of health care and appropriate allocation of available resources for the treatment of patients with breast cancer. This is of particular...
6.
McDonald S, Stevenson D, Moir S, Hutcheon A, Haites N, Heys S, et al.
Eur J Cancer
. 2005 May;
41(7):1086-94.
PMID: 15862759
Docetaxel is one of the most effective chemotherapeutic agents in the treatment of breast cancer. Breast cancers can have an inherent or acquired resistance to docetaxel but the causes of...
7.
Evans T, Yellowlees A, Foster E, Earl H, Cameron D, Hutcheon A, et al.
J Clin Oncol
. 2005 Apr;
23(13):2988-95.
PMID: 15860854
PURPOSE To compare the clinical and pathologic response rates of doxorubicin and cyclophosphamide (AC) with doxorubicin and docetaxel (AD) as primary chemotherapy in women with primary or locally advanced breast...
8.
Heys S, Sarkar T, Hutcheon A
Breast Cancer Res Treat
. 2005 Apr;
90(2):169-85.
PMID: 15803364
Primary chemotherapy achieves high clinical response rates and facilitates breast conservation in many patients with large and locally advanced breast cancer. It may also serve to indicate responsiveness to chemotherapeutic...
9.
Heys S, Sarkar T, Hutcheon A
Expert Opin Pharmacother
. 2004 Oct;
5(10):2147-57.
PMID: 15461550
Developments in the role of adjuvant and neoadjuvant chemotherapy for the treatment of patients with breast cancer have focused on the taxes, in particular, docetaxel. This paper discusses the rationale...
10.
Ogston K, Miller I, Schofield A, Spyrantis A, Pavlidou E, Sarkar T, et al.
Breast Cancer Res Treat
. 2004 Aug;
86(2):181-9.
PMID: 15319570
Purpose: Primary chemotherapy is commonly used in patients with breast cancer to downstage the primary tumour prior to surgery. There is a need to establish, prior to commencement of chemotherapy,...